A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 9ER
- Sponsors Bristol-Myers Squibb
- 09 Apr 2018 Planned End Date changed from 21 Apr 2023 to 22 Apr 2023.
- 12 Feb 2018 Enrollment to the triplet arm was discontinued by protocol amendment
- 12 Feb 2018 Planned number of patients changed from 1014 to 630.